| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15229365 | IVR | 2.6 mmol/kg | 2.6 mmol/kg | Affects tryptophan metabolism | Metabolic endocrine-mediated perturbations |
| PMID:17241728 | IVR | 0.00003 mg/L | 0.00003 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.0004 mg/L | 0.0004 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:17574328 | IVTH | 0.000001 M | 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0003 M | 0.0003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:17654256 | IVR | 10 mg/kg | - | No significant effects observed | - |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| PMID:19165384 | IVTH | 0.0001 M | 0.0001 M | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| PMID:19501113 | IVTH | 0.0006 - 0.5 mmol/L | 0.5 mmol/L | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0006 - 0.5 mmol/L | 0.167 - 0.5 mmol/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:22240090 | IVR | 9.2 mg/kg/day | 9.2 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVR | 92.7 mg/kg/day | 92.7 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVR | 46.3 mg/kg/day | 46.3 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:26597031 | IVTH | 0.00005 M | 0.00005 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00018 M | 0.00018 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00018 M | 0.00018 M | Induce apoptosis of placental cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | - | No significant effects observed | - | |
| IVTH | 0.000025 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Induce apoptosis of placental cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| PMID:26871967 | IVTH | 0.00005 M | 0.00005 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00018 M | 0.00018 M | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00018 M | 0.00018 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000025 M | 0.000025 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| PMID:28238932 | IVR | 800 mg/kg | 800 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| PMID:30810372 | IVTH | 0.0000001 M | 0.0000001 M | Affects placental differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Increased hCG levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Increased hCG levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects placental differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects placental differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Increased hCG levels | Reproductive endocrine-mediated perturbations | |
| PMID:30847963 | IVTH | 0.002 - 2 mg/L | 80 - 40 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| PMID:30909102 | IVTH | 0.0000001 M | - | No significant effects observed | - |
| IVTH | 0.00001 M | - | No significant effects observed | - | |
| IVTH | 0.00000001 M | - | No significant effects observed | - | |
| IVTH | 0.000000001 M | - | No significant effects observed | - | |
| IVTH | 0.000001 M | - | No significant effects observed | - | |
| IVTH | 0.0000000001 M | 0.0000000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31771930 | IVTH | 0.0002 M | 0.0002 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0002 M | 0.0002 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0005 M | 0.0005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0005 M | 0.0005 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002 M | 0.00002 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002 M | 0.00002 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:32027815 | IVTH | 0.000000001 - 0.00002 M | 0.000000001 - 0.00002 M | Reduced sperm quality | Reproductive endocrine-mediated perturbations |
| PMID:32334352 | IVTH | 0.0001 - 0.001 M | 0.0001 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000025 - 0.0025 M | 0.00000025 - 0.0025 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000025 - 0.0025 M | 0.00000025 - 0.0025 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000025 - 0.0025 M | 0.0000025 - 0.0025 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:33027880 | IVTH | 0.000001 - 0.0001 M | 0.000001 - 0.0001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.00001 - 1 mg/kg | 0.00001 - 1 mg/kg | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 - 1 M | 0.00001 - 1 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| PMID:34792101 | IVTH | 0.00005 - 0.0001 M | 0.00005 - 0.0001 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations |
| PMID:34910997 | IVTH | 0.0000001 M | 0.0000001 M | No significant effects observed | - |
| IVTH | 0.0000001 M | 0.0000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:36060944 | IVTH | 0.000001 M | 0.000001 M | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| PMID:36607728 | IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Changes in morphology of pancreas | Metabolic endocrine-mediated perturbations | |
| IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Decreased pancreas weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:38685446 | IVTH | 0.02051 M | 0.02051 M | Follicular atresia | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00002051 - 0.02051 M | 0.00002051 - 0.02051 M | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002051 - 0.02051 M | 0.00002051 - 0.02051 M | Changes in morphology of granulosa cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00002051 - 0.02051 M | 0.00002051 - 0.02051 M | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:38981393 | IVTH | 0.0002 M | 0.0002 M | Affects ovarian development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.0002 - 0.0003 M | 0.0002 - 0.0003 M | Oxidative stress in granulosa cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0002 - 0.0003 M | 0.0002 - 0.0003 M | Induce apoptosis of granulosa cells | Reproductive endocrine-mediated perturbations | |
| PMID:39341470 | IVTH | 0.00003 M | 0.00003 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:39555414 | IVR | 1 mg/kg | 1 mg/kg | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decreased pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Altered gut metabolite levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.